P6238Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials
Vallejo-Vaz, A.J., Roth, E.M., Hovingh, G.K., Louie, M.J., Valcheva, V., Letierce, A., Ray, K.K.Volume:
38
Language:
english
Journal:
European Heart Journal
DOI:
10.1093/eurheartj/ehx493.P6238
Date:
August, 2017
File:
PDF, 90 KB
english, 2017